Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.

Autor: Mhibik M; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Gaglione EM; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Eik D; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Herrick J; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Le J; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Ahn IE; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Chiu C; Genmab, Princeton, NJ., Wielgos-Bonvallet M; Genmab, Princeton, NJ., Hiemstra IH; Genmab, Utrecht, The Netherlands., Breij ECW; Genmab, Utrecht, The Netherlands., Chen J; Genmab, Princeton, NJ., Reilly EB; AbbVie Inc, North Chicago, IL., Epling-Burnette PK; AbbVie Inc, North Chicago, IL., Szafer-Glusman E; AbbVie Inc, Sunnyvale, CA., Sun C; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Wiestner A; Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

Publikováno v: Blood advances [Blood Adv] 2023 Aug 08; Vol. 7 (15), pp. 4089-4101.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Autor: Bast RC Jr; University of Texas MD Anderson Cancer Center, Houston, Texas., Matulonis UA; Dana-Farber Cancer Institute, Boston, Massachusetts., Sood AK; University of Texas MD Anderson Cancer Center, Houston, Texas., Ahmed AA; University of Oxford, Oxford, United Kingdom., Amobi AE; Roswell Park Cancer Institute, Buffalo, New York., Balkwill FR; Barts Cancer Institute, London, United Kingdom., Wielgos-Bonvallet M; NYU Langone Medical Center, New York, New York., Bowtell DDL; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia., Brenton JD; University of Cambridge, Cambridge, United Kingdom., Brugge JS; Harvard Medical School, Boston, Massachusetts., Coleman RL; University of Texas MD Anderson Cancer Center, Houston, Texas., Draetta GF; University of Texas MD Anderson Cancer Center, Houston, Texas., Doberstein K; University of Pennsylvania, Philadelphia, Pennsylvania., Drapkin RI; University of Pennsylvania, Philadelphia, Pennsylvania., Eckert MA; University of Chicago, Chicago, Illinois., Edwards RP; University of Pittsburgh, Pittsburgh, Pennsylvania., Elias KM; Brigham and Women's Hospital, Boston, Massachusetts., Ennis D; University of Glasgow, Glasgow, United Kingdom., Futreal A; University of Texas MD Anderson Cancer Center, Houston, Texas., Gershenson DM; University of Texas MD Anderson Cancer Center, Houston, Texas., Greenberg RA; University of Chicago, Chicago, Illinois., Huntsman DG; University of British Columbia, Vancouver, British Columbia, Canada., Ji JXY; University of British Columbia, Vancouver, British Columbia, Canada., Kohn EC; CTEP NCI, Rockville, Maryland., Iavarone C; Harvard Medical School, Boston, Massachusetts., Lengyel ER; University of Chicago, Chicago, Illinois., Levine DA; NYU Langone Medical Center, New York, New York., Lord CJ; Institute of Cancer Research, London, United Kingdom., Lu Z; University of Texas MD Anderson Cancer Center, Houston, Texas., Mills GB; University of Texas MD Anderson Cancer Center, Houston, Texas., Modugno F; University of Pittsburgh, Pittsburgh, Pennsylvania., Nelson BH; University of British Columbia, Vancouver, British Columbia, Canada.; BC Cancer Agency, Vancouver, British Columbia, Canada., Odunsi K; Roswell Park Cancer Institute, Buffalo, New York., Pilsworth JA; University of British Columbia, Vancouver, British Columbia, Canada., Rottapel RK; University of Toronto, Toronto, Ontario, Canada., Powell DJ Jr; University of Pennsylvania, Philadelphia, Pennsylvania., Shen L; Roswell Park Cancer Institute, Buffalo, New York., Shih IM; Johns Hopkins University School of Medicine, Baltimore, Maryland., Spriggs DR; Massachusetts General Hospital, Boston, Massachusetts., Walton J; University of Glasgow, Glasgow, United Kingdom., Zhang K; University of Helsinki, Helsinki, Finland., Zhang R; The Wistar Institute, Philadelphia, Pennsylvania., Zou L; Massachusetts General Hospital, Boston, Massachusetts.

Publikováno v: Cancer [Cancer] 2019 Jun 15; Vol. 125 (12), pp. 1963-1972. Date of Electronic Publication: 2019 Mar 05.

Novel LIPA-Targeted Therapy for Treating Ovarian Cancer.

Autor: Collier, Alexia B.¹ (AUTHOR) alexia.collier@bcm.edu, Viswanadhapalli, Suryavathi^1,2 (AUTHOR) viswanadhapa@uthscsa.edu, Gopalam, Rahul¹ (AUTHOR) gopalam.rahul@gmail.com, Lee, Tae-Kyung³ (AUTHOR) leetk92@gmail.com, Kassees, Kara³ (AUTHOR) kara.kassees@utdallas.edu, Parra, Karla⁴ (AUTHOR) karla.parra@utsouthwestern.edu, Sharma, Gaurav⁴ (AUTHOR) gaurav.sharma4@utsouthwestern.edu, Reese, Tanner C.⁴ (AUTHOR) tanner.reese@utsouthwestern.edu, Liu, Xihui⁴ (AUTHOR) liuxihui@outlook.com, Yang, Xue¹ (AUTHOR) yangx1@uthscsa.edu, Ebrahimi, Behnam¹ (AUTHOR) ebrahimib1@livemail.uthscsa.edu, Pratap, Uday P.¹ (AUTHOR) pratap@uthscsa.edu, Mahajan, Megharani¹ (AUTHOR) mahajanm@uthscsa.edu, Arnold, William C.¹ (AUTHOR) arnoldw@uthscsa.edu, Baker, Adriana¹ (AUTHOR) bakera5@livemail.uthscsa.edu, Chen, Chia-Yuan³ (AUTHOR) chiayuan.chen@utdallas.edu, Elmore, Scott Terry³ (AUTHOR) scott.elmore@utdallas.edu, Subbarayalu, Panneerdoss⁵ (AUTHOR) subbarayalu@uthscsa.edu, Sareddy, Gangadhara R.^1,2 (AUTHOR) sareddy@uthscsa.edu, Valente, Philip T.¹ (AUTHOR) valentep@uthscsa.edu

Publikováno v: Cancers. Feb2024, Vol. 16 Issue 3, p500. 15p.

PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS.

Autor: Chiu, C. W., Hiemstra, I. H., ten Hagen, W., Snijdewint‐Nkairi, R., de Jong, B., Garrido Castro, P., Kweekel, C., Oliveri, R. S., Elliot, B., Wielgos‐Bonvallet, M., Szafer‐Glusman, E., Schuurhuis, D., Blaedel, J., Ahmadi, T., Breij, E., Sasser, A.K., Jure‐Kunkel, M.

Publikováno v: Hematological Oncology; Jun2021 Supplement S2, Vol. 39, p1-2, 2p

Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.

Autor: Stur, Elaine¹ (AUTHOR), Bayraktar, Emine¹ (AUTHOR), Dal Molin, Graziela Zibetti² (AUTHOR), Wu, Sherry Y.³ (AUTHOR), Mangala, Lingegowda S.¹ (AUTHOR), Yao, Hui⁴ (AUTHOR), Wang, Ying⁴ (AUTHOR), Ram, Prahlad T.⁵ (AUTHOR), Corvigno, Sara¹ (AUTHOR), Chen, Hu⁴ (AUTHOR), Liang, Han⁴ (AUTHOR), Tworoger, Shelley S.⁶ (AUTHOR), Levine, Douglas A.⁷ (AUTHOR), Lutgendorf, Susan K.⁸ (AUTHOR), Liu, Jinsong⁹ (AUTHOR), Moore, Kathleen N.¹⁰ (AUTHOR), Baggerly, Keith A.⁴ (AUTHOR), Karlan, Beth Y.¹¹ (AUTHOR), Sood, Anil K.¹ (AUTHOR) asood@mdanderson.org

Publikováno v: Cancers. Sep2022, Vol. 14 Issue 17, p4198. 16p.